Mitochondrial and glycolytic metabolic compartmentalization in Diffuse Large B Cell Lymphoma
Metabolic heterogeneity between neoplastic cells and surrounding stroma has been described in several epithelial malignancies; however, the metabolic phenotypes of neoplastic lymphocytes and neighboring stroma in diffuse large B-cell lymphoma (DLBCL) is unknown. We investigated the metabolic phenotypes of human DLBCL tumors by using immunohistochemical markers of glycolytic and mitochondrial oxidative phosphorylation (OXPHOS) metabolism. The lactate importer MCT4 is a marker of glycolysis, whereas the lactate importer MCT1 and TOMM20 are markers of OXPHOS metabolism. (Source: Seminars in Oncology)
Source: Seminars in Oncology - October 10, 2017 Category: Cancer & Oncology Authors: Mahasweta Gooptu, Diana Whitaker-Menezes, John Sprandio, Marina Domingo-Vidal, Zhao Lin, Guldeep Uppal, Jerald Gong, Roberto Fratamico, Benjamin Leiby, Alina Dulau-Florea, Jaime Caro, Ubaldo Martinez-Outschoorn Source Type: research
Pilot study demonstrating metabolic and anti-proliferative effects of in vivo anti-oxidant supplementation with N-Acetylcysteine in Breast Cancer
High oxidative stress as defined by hydroxyl and peroxyl activity is often found in the stroma of human breast cancers. Oxidative stress induces stromal catabolism, which promotes cancer aggressiveness. Stromal cells exposed to oxidative stress release catabolites such as lactate, which are up-taken by cancer cells to support mitochondrial oxidative phosphorylation. The transfer of catabolites between stromal and cancer cells leads to metabolic heterogeneity between these cells and increased cancer cell proliferation and reduced apoptosis in preclinical models. (Source: Seminars in Oncology)
Source: Seminars in Oncology - October 10, 2017 Category: Cancer & Oncology Authors: Daniel Monti, Federica Sotgia, Diana Whitaker Menezes, Madalina Tuluc, Ruth Birbe, Adam Berger, Melissa Lazar, Paolo Cotzia, Rossitza Draganova-Tacheva, Zhao Lin, Marina Domingo-Vidal, Andrew Newberg, Michael P. Lisanti, Ubaldo Martinez-Outschoorn Source Type: research
outside front cover
(Source: Seminars in Oncology)
Source: Seminars in Oncology - October 1, 2017 Category: Cancer & Oncology Source Type: research
Masthead
(Source: Seminars in Oncology)
Source: Seminars in Oncology - October 1, 2017 Category: Cancer & Oncology Source Type: research
Editorial Board
(Source: Seminars in Oncology)
Source: Seminars in Oncology - October 1, 2017 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Seminars in Oncology)
Source: Seminars in Oncology - October 1, 2017 Category: Cancer & Oncology Source Type: research
outside front cover
(Source: Seminars in Oncology)
Source: Seminars in Oncology - October 1, 2017 Category: Cancer & Oncology Source Type: research
Masthead
(Source: Seminars in Oncology)
Source: Seminars in Oncology - October 1, 2017 Category: Cancer & Oncology Source Type: research
Editorial Board
(Source: Seminars in Oncology)
Source: Seminars in Oncology - October 1, 2017 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Seminars in Oncology)
Source: Seminars in Oncology - October 1, 2017 Category: Cancer & Oncology Source Type: research
Response to letter to the editor on ‘Mind the gap’
We thank Professor Zalcberg and Michael Wonder for their letter (Semin Oncol [in press]). We are satisfied that our methods [1] support the conclusion that it is better to selectively fund new medicines demonstrating clear clinical benefit and that are cost-effective and affordable---where new cancer medicines are not the sole arbiters of cancer survival differences between countries. (Source: Seminars in Oncology)
Source: Seminars in Oncology - September 15, 2017 Category: Cancer & Oncology Authors: Scott Metcalfe, Jackie Evans, R. Matthew Strother, George Laking, Tony Wang, Steffan Crausaz Source Type: research
Guidance Statement on BRCA1/2 Tumor Testing in Ovarian Cancer Patients
The approval in 2015 of the first poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib [Lynparza ™]) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with ovarian cancer. Ovarian cancer patients are now being referred for BRCA1/2 genetic testing for treatment decisions, in addition to familial risk estimation, and irrespective of a family history of breast/ovarian cancer. (Source: Seminars in Oncology)
Source: Seminars in Oncology - September 15, 2017 Category: Cancer & Oncology Authors: Ettore Capoluongo, Gillian Ellison, Jos é Antonio López-Guerrero, Frederique Penault-Llorca, Marjolijn J.L. Ligtenberg, Susana Banerjee, Christian Singer, Eitan Friedman, Birgid Markiefka, Peter Schirmacher, Reinhard Büttner, Christi J. van Asperen, Is Source Type: research
Response to letter to the editor
Dear Editor, (Source: Seminars in Oncology)
Source: Seminars in Oncology - September 15, 2017 Category: Cancer & Oncology Authors: Scott Metcalfe, Jackie Evans, George Laking, R. Matthew Strother, Tony Wang, Steffan Crausaz Source Type: research
Commentary: Somatostatin analogs —How we choose, and why
Octreotide long-acting release (LAR) has been used since the early 1990s to slow tumor growth in well differentiated neuroendocrine tumors (NETs). The original registration for octreotide LAR was for control of hormone-related symptoms; however, prolonged progression-free survival (PFS) was shown in the PROMID study, a randomized, double-blind, placebo-controlled trial in midgut NETs [1]. That study was not powered to evaluate overall survival, and the data were never submitted to regulatory authorities to seek an indication for octreotide LAR as an antineoplastic agent. (Source: Seminars in Oncology)
Source: Seminars in Oncology - August 4, 2017 Category: Cancer & Oncology Authors: Diane Reidy-Lagunes, Nitya Raj, Leonard Saltz Source Type: research
